Fresenius Medical Care Corporation (NYSE:FMS)‘s stock had its “buy” rating reissued by DZ Bank AG in a report released on Monday.

Other research analysts also recently issued research reports about the company. BidaskClub downgraded Fresenius Medical Care Corporation from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. Zacks Investment Research upgraded Fresenius Medical Care Corporation from a “sell” rating to a “hold” rating and set a $53.00 target price for the company in a research note on Monday, October 9th. Finally, Royal Bank Of Canada restated a “hold” rating and issued a $44.00 target price on shares of Fresenius Medical Care Corporation in a research note on Wednesday, September 13th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $48.50.

Fresenius Medical Care Corporation (NYSE FMS) opened at $48.42 on Monday. Fresenius Medical Care Corporation has a 12 month low of $38.05 and a 12 month high of $50.22. The company has a quick ratio of 0.98, a current ratio of 1.22 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $29,813.26, a PE ratio of 21.71, a price-to-earnings-growth ratio of 2.18 and a beta of 0.45.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.watchlistnews.com/fresenius-medical-care-corporation-fms-stock-rating-reaffirmed-by-dz-bank-ag/1699607.html.

Institutional investors and hedge funds have recently modified their holdings of the company. UBS Asset Management Americas Inc. boosted its position in shares of Fresenius Medical Care Corporation by 3.6% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 2,357 shares of the company’s stock valued at $114,000 after acquiring an additional 81 shares during the last quarter. Pacer Advisors Inc. bought a new stake in shares of Fresenius Medical Care Corporation during the 2nd quarter valued at about $179,000. FFT Wealth Management LLC bought a new stake in shares of Fresenius Medical Care Corporation during the 2nd quarter valued at about $201,000. HPM Partners LLC bought a new stake in shares of Fresenius Medical Care Corporation during the 2nd quarter valued at about $221,000. Finally, YorkBridge Wealth Partners LLC boosted its position in shares of Fresenius Medical Care Corporation by 19.4% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 4,613 shares of the company’s stock valued at $222,000 after acquiring an additional 749 shares during the last quarter. Hedge funds and other institutional investors own 2.62% of the company’s stock.

About Fresenius Medical Care Corporation

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Analyst Recommendations for Fresenius Medical Care Corporation (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.